Fenfluramine is a substituted amphetamine and potent serotonin releasing agent that lived two dramatically different lives in pharmacology. First developed by the French pharmaceutical company Servier in the early 1960s, it was marketed as Pondimin for obesity management and became one half of the infamous "fen-phen" combination that swept the United States in the 1990s -- at its peak, over 18 million prescriptions were written in the US alone. Then it all collapsed. In September 1997, the Mayo Clinic published a case series of 24 patients with cardiac valvulopathy, the FDA pulled fenfluramine from the market, and what followed was $13-14 billion in legal damages in one of the largest pharmaceutical settlements in history.
But fenfluramine refused to die. Belgian researchers studying Dravet syndrome -- a rare, devastating form of childhood epilepsy -- discovered that low-dose fenfluramine dramatically reduced seizure frequency in children who had failed every other treatment. The FDA approved it in 2020 as Fintepla, and the DEA descheduled it entirely in 2022, removing it from Schedule IV. Today it is not a controlled substance in the United States.
What makes fenfluramine pharmacologically interesting is the gap between its mechanism and its reputation. It is a substrate-type serotonin releaser -- like MDMA, it enters presynaptic terminals through the serotonin transporter and reverses the pump, flooding the synapse with 5-HT. But unlike MDMA, it barely touches dopamine. This gives it a subjective profile that is strikingly different from what you would expect from an amphetamine: sedation rather than stimulation, anxiolysis rather than euphoria, appetite suppression without the manic focus. Users on the South African rave scene, where fenfluramine was reportedly popular, described it as relaxing but flat -- lacking the empathogenic warmth of MDMA and the drive of traditional stimulants. The single Erowid experience report calls it "quite anxiolytic, easing social interaction" but notes it lacks the characteristic euphoric intensity people seek from entactogens.
The cardiac story is the defining feature of fenfluramine's pharmacology. Its primary metabolite, norfenfluramine, is a potent full agonist at 5-HT2B receptors on cardiac valvular interstitial cells. Chronic activation of these receptors causes the cells to proliferate and lay down fibrotic tissue, thickening heart valve leaflets into glistening white plaques that progressively destroy valve function. Up to 30% of chronic users in post-withdrawal studies showed abnormal echocardiograms. This is not a theoretical risk or a rare idiosyncratic reaction -- it is a dose-dependent, mechanism-based toxicity that ended one of the largest diet drug markets in pharmaceutical history. Current Fintepla prescribing requires echocardiogram monitoring before treatment, every six months during treatment, and three to six months after stopping.
Recreationally, fenfluramine is a footnote. There is no PsychonautWiki page. There is one Erowid report. Reddit discussions focus almost entirely on its epilepsy applications. At very high doses (240-600 mg), clinical studies documented LSD-like hallucinogenic episodes with visual, olfactory, and somatic hallucinations -- but the overall experience was described as "unpleasant, sedative, and qualitatively different from amphetamine." The cardiac risks alone make recreational exploration genuinely dangerous in a way that most substances are not: even moderate chronic use can cause irreversible structural damage to the heart.